Marathon Oil Corporation (MRO) failed to extend gains with the stock declining -0.25% or $-0.04 to close the day at $16.08 on light trading volume of 13.5M shares, compared to its three month average trading volume of 17.54M. The Houston Texas 77056 based company has been underperforming the independent oil & gas group over the past 52 weeks, with the stock losing -14.64%, compared to the industry which has advanced 5.82% over the same period. With RSI of 59.54, the stock should still continue to rise and get closer to its one year target estimate of $18.2, making it a hold for now.
Marathon Oil Corporation operates as an energy company. It operates through three segments: North America E&P, International E&P, and Oil Sands Mining. The North America E&P segment develops, explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in North America. The International Exploration and Production segment explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in Equatorial Guinea, Gabon, the Kurdistan Region of Iraq, Libya, and the United Kingdom; and produces and markets products manufactured from natural gas, such as liquefied natural gas and methanol in Equatorial Guinea. The Oil Sands Mining segment mines, extracts, and transports bitumen from oil sands deposits in Alberta and Canada; and upgrades the bitumen to produce and market synthetic crude oil and vacuum gas oil. As of December 31, 2015, it had rights to participate in developed and undeveloped leases totaling approximately 32,000 net acres. The company was formerly known as USX Corporation and changed its name to Marathon Oil Corporation in July 2001. Marathon Oil Corporation was founded in 1887 and is headquartered in Houston, Texas.
Novavax, Inc. (NVAX) fell -6.47% during last trading as the stock lost $-0.13 to finish the day at $1.88 with about 13.26M shares changing hands, compared to its three month average trading volume of 16.17M. The $504.89M market cap company, which fluctuated between $1.87 and $2 during the day, currently situated 62.07% above its 52 week low of $1.16 and -79.63% away from its one year high of $9.23. The RSI of 26.03 indicates the stock is oversold at the current levels, buy for now.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization that are in Phase III clinical trials, as well as pediatric RSV candidate, which is in Phase I clinical trial; seasonal quadrivalent influenza and pandemic H7N9 vaccines, which are in Phase II clinical trials; vaccine candidate against Ebola Virus that is Phase I clinical trial, as well as combination respiratory vaccine candidate and seasonal influenza vaccine candidate that is in pre-clinical trial; and rabies G protein vaccine candidate, which is in Phase I/II clinical trial. The company also has pre-clinical stage programs for various infectious diseases, including the Middle East respiratory syndrome coronavirus; and develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
CSX Corp. (CSX) saw its value increase by 1.14% as the stock gained $0.35 to finish the day at a closing price of $31.06. The stock was higher in trading and has fluctuated between $21.33-$31.16 per share for the past year. The shares, which traded within a range of $30.6 to $31.16 during the day, are up by 17.83% in the past three months and up by 26.93% over the past six months. It is currently trading 5.28% above its 20 day moving average and 8.31% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $30.41 a share over the next twelve months. The current relative strength index (RSI) reading is 72.69. The technical indicator do not lead us to believe the stock will see more gains any time soon.
CSX Corporation, together with its subsidiaries, provides rail-based transportation services in the United States and Canada. The company offers rail services, as well as transports intermodal containers and trailers. It transports agricultural products, phosphates and fertilizers, food and consumer products, chemicals, automotive products, metals, forest products, minerals, and waste and equipment; and coal, coke, and iron ore to electricity-generating power plants, steel manufacturers, and industrial plants. The company also exports coal to deep-water port facilities. In addition, it offers intermodal transportation services through a network of approximately 50 terminals transporting manufactured consumer goods in containers in the eastern United States; drayage services, including the pickup and delivery of intermodal shipments; and trucking dispatch services. Further, the company serves the automotive industry with distribution centers and storage locations, as well as connects non-rail served customers through transferring products from rail to trucks, which includes plastics and ethanol. Additionally, it acquires, develops, sells, leases, and manages real estate properties. The company operates approximately 21,000 route mile rail network, which serves various population centers in 23 states east of the Mississippi River, the District of Columbia, and the Canadian provinces of Ontario and Quebec, as well as owns and leases approximately 4,500 locomotives. It also serves production and distribution facilities through track connections. CSX Corporation was founded in 1978 and is based in Jacksonville, Florida.